Showing 1 - 5 of 5 Items
Showing 1 - 5 of 5 Items
Sort By: Relevance
Journal Article
|Research
2022-05-01 • Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
2022-05-01 • Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
BACKGROUND
The novel urine-based FujiLAM test identifies tuberculosis in HIV-positive patients but may be challenging to use at point-of-care (POC).
OBJECTIVES
We assess...
The novel urine-based FujiLAM test identifies tuberculosis in HIV-positive patients but may be challenging to use at point-of-care (POC).
OBJECTIVES
We assess...
Journal Article
|Research
2020-12-23 • Open Forum Infectious Diseases
2020-12-23 • Open Forum Infectious Diseases
BACKGROUND
Diagnosing tuberculosis (TB), the leading cause of death in people with HIV, remains a challenge in resource-limited countries. We assessed TB diagnosis using a strategy t...
Diagnosing tuberculosis (TB), the leading cause of death in people with HIV, remains a challenge in resource-limited countries. We assessed TB diagnosis using a strategy t...
Journal Article
|Research
2019-04-30 • PLOS Medicine
2019-04-30 • PLOS Medicine
BACKGROUND:
Current guidelines recommend the use of the lateral flow urine lipoarabinomannan assay (LAM) in HIV-positive, ambulatory patients with signs and symptoms of tuberculosis...
Current guidelines recommend the use of the lateral flow urine lipoarabinomannan assay (LAM) in HIV-positive, ambulatory patients with signs and symptoms of tuberculosis...
Journal Article
|Research
2020-01-01 • Journal of Acquired Immune Deficiency Syndromes (1999)
2020-01-01 • Journal of Acquired Immune Deficiency Syndromes (1999)
Background: Current eligibility criteria for urine lateral-flow-lipoarabinomannan assay (LF-LAM) in ambulatory, HIV-positive patients rely on the CD4 count. We investigated the diagnosti...
Journal Article
|Research
2022-05-16 • Journal of Infection
2022-05-16 • Journal of Infection
BACKGROUND
WHO recommends urine lateral-flow lipoarabinomannan (LF-LAM) testing with AlereLAM in HIV-positive inpatients only if screening criteria are met. We assessed the performan...
WHO recommends urine lateral-flow lipoarabinomannan (LF-LAM) testing with AlereLAM in HIV-positive inpatients only if screening criteria are met. We assessed the performan...